NL-OMON56013
Not yet recruiting
Not Applicable
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study. - Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Allograft rejection
- Sponsor
- Sangamo Therapeutics France SAS
- Enrollment
- 8
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects who enrolled in the Phase I/IIa study TX200\-KT02, received a
- •transplanted kidney and have either completed or withdrawn from that study.
- •2\. Willing and able to provide written informed consent (IC) in accordance with
- •local regulations and governing Independent Ethics Committee
- •(IEC)/Institutional Review Board (IRB) requirements prior to any procedure or
- •evaluation performed specifically for the sole purpose of the study.
Exclusion Criteria
- •1\. Subjects/persons committed to an institution following an administrative or
- •judicial order.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-002440-40-DESangamo Therapeutics France SAS15
Recruiting
Phase 1
ong-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Kidney Transplant RejectionMedDRA version: 21.1Level: LLTClassification code: 10050436Term: Prophylaxis against renal transplant rejection Class: 10042613Therapeutic area: Phenomena and Processes [G] - Immune system processes [G12]CTIS2024-512580-31-00Sangamo Therapeutics France30
Active, not recruiting
Phase 1
ong term follow up for patients who have received NiCord/CordIn, stem cells from donated umbilical cord bloodthat were grown in a laboratory to expand their numberHigh risk haematological malignanciesHemoglobinopathiesMedDRA version: 18.1Level: LLTClassification code 10025316Term: Lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10040645Term: Sickle cell disease NOSSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-004813-26-ESGamida Cell Ltd76
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.CTIS2024-511684-28-00Autolus Limited111
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with an Autolus CAR T cell therapyEUCTR2016-004867-38-NLAutolus Limited500